SAKK PRODIGE 32: Systematic surgery vs monitoring and salvage surgery in opera-ble oesophageal cancer in complete clinical response after chemoradiation Strategic multicenter randomized phase II- III trial
|
abstract
|
Patients with locally advanced oesophageal cancer are evaluable for
a participation in this trial. The standard treatment for these
patients is neoadjuvant chemoradia-tion followed by surgery.
Patients receiving a complete pathological remission after
neoadjuvant therapy have a 5y-survival of 75-80% (Swiss data),
patients with macro-scopic tumor left do much worse with a 5y
survival rate of only about 40%. The direct oesophagectomy is the
international standard however, it has itself a relevant long-term
morbidity and a mortality of 5-10%. Therefore, it exists a chronic
controversy whether patients with good response after neoadjuvant
therapy should still be operated or not, assuming this operation is
without rele-vant impact on survival but increases the morbidity and
mortality only.
|
| |
|
|
type of project
|
clinical studies
|
|
status
|
ongoing - recruiting phase
|
|
start of project
|
2017
|
|
end of project
|
2024
|
|
study design
|
Phase II - III
|
|
responsible person
|
PD Dr. med. Thomas Ruhstaller
|
additional links & downloads
